JPS60258207A - 診断試薬用ラテックス - Google Patents
診断試薬用ラテックスInfo
- Publication number
- JPS60258207A JPS60258207A JP11578584A JP11578584A JPS60258207A JP S60258207 A JPS60258207 A JP S60258207A JP 11578584 A JP11578584 A JP 11578584A JP 11578584 A JP11578584 A JP 11578584A JP S60258207 A JPS60258207 A JP S60258207A
- Authority
- JP
- Japan
- Prior art keywords
- latex
- polystyrene
- hours
- suspension
- carried out
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004816 latex Substances 0.000 title claims abstract description 134
- 229920000126 latex Polymers 0.000 title claims abstract description 134
- 238000002360 preparation method Methods 0.000 title description 7
- 239000004793 Polystyrene Substances 0.000 claims abstract description 59
- 229920002223 polystyrene Polymers 0.000 claims abstract description 59
- 239000002245 particle Substances 0.000 claims abstract description 42
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 27
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 25
- 238000005660 chlorination reaction Methods 0.000 claims abstract description 24
- 239000000725 suspension Substances 0.000 claims abstract description 19
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 15
- 239000003999 initiator Substances 0.000 claims abstract description 11
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 claims abstract description 10
- 230000002378 acidificating effect Effects 0.000 claims abstract description 9
- 230000007935 neutral effect Effects 0.000 claims abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 25
- 230000005484 gravity Effects 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 9
- 230000000379 polymerizing effect Effects 0.000 claims description 4
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 abstract description 5
- 238000004132 cross linking Methods 0.000 abstract description 4
- 229920000642 polymer Polymers 0.000 abstract description 2
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 40
- 238000012360 testing method Methods 0.000 description 22
- 238000004220 aggregation Methods 0.000 description 21
- 239000000427 antigen Substances 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 230000002776 aggregation Effects 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 230000004520 agglutination Effects 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 9
- 210000000601 blood cell Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 229910001873 dinitrogen Inorganic materials 0.000 description 5
- 230000035931 haemagglutination Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 238000010926 purge Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000011891 EIA kit Methods 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- -1 antiserum Substances 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- SBYMUDUGTIKLCR-UHFFFAOYSA-N 2-chloroethenylbenzene Chemical compound ClC=CC1=CC=CC=C1 SBYMUDUGTIKLCR-UHFFFAOYSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 1
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000015115 caffè latte Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical group OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- HJWLCRVIBGQPNF-UHFFFAOYSA-N prop-2-enylbenzene Chemical compound C=CCC1=CC=CC=C1 HJWLCRVIBGQPNF-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11578584A JPS60258207A (ja) | 1984-06-05 | 1984-06-05 | 診断試薬用ラテックス |
| US06/710,234 US4605686A (en) | 1984-03-13 | 1985-03-11 | Latex for immunoserological tests and a method for the production of the same |
| ES541181A ES8700675A1 (es) | 1984-03-13 | 1985-03-12 | Un metodo de producir un latex para ensayos inmunoserologi- cos |
| EP85301683A EP0158443B1 (en) | 1984-03-13 | 1985-03-12 | A latex for immunoserological tests and a method of producing the same |
| DE8585301683T DE3585045D1 (de) | 1984-03-13 | 1985-03-12 | Ein latex fuer immunoserologische teste und ein verfahren zu seiner herstellung. |
| CA000476291A CA1250805A (en) | 1984-03-13 | 1985-03-12 | Latex for immunoserological tests and a method for the production of the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11578584A JPS60258207A (ja) | 1984-06-05 | 1984-06-05 | 診断試薬用ラテックス |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60258207A true JPS60258207A (ja) | 1985-12-20 |
| JPH0212484B2 JPH0212484B2 (enrdf_load_stackoverflow) | 1990-03-20 |
Family
ID=14671002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11578584A Granted JPS60258207A (ja) | 1984-03-13 | 1984-06-05 | 診断試薬用ラテックス |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60258207A (enrdf_load_stackoverflow) |
-
1984
- 1984-06-05 JP JP11578584A patent/JPS60258207A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0212484B2 (enrdf_load_stackoverflow) | 1990-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4605686A (en) | Latex for immunoserological tests and a method for the production of the same | |
| JP2834138B2 (ja) | 抗原被覆ラテックスの凝集によるヒト免疫不全ウイルスに対する抗体の検出 | |
| AU608753B2 (en) | Dispersion polymers, processes for their preparation and their use | |
| JPH05310849A (ja) | 多官能性親水性球状微粒子、その製造方法及びその使用方法 | |
| JPH02194360A (ja) | カルボキシル基含有重合体を含む免疫化学試験用剤 | |
| JPH028271B2 (enrdf_load_stackoverflow) | ||
| WO2018043584A1 (ja) | 異なる方式で抗原を固定化した抗原担持不溶性担体粒子を用いる抗体測定法、抗体測定用試薬 | |
| JPS60258207A (ja) | 診断試薬用ラテックス | |
| JP4646270B2 (ja) | 抗リン脂質抗体測定試薬に用いる不溶性担体、抗リン脂質抗体測定試薬、及び、抗リン脂質抗体の測定方法 | |
| JPS60192262A (ja) | 免疫凝集反応に用いるための担体 | |
| JPH0527825B2 (enrdf_load_stackoverflow) | ||
| JPS60233105A (ja) | 診断試薬用ラテツクスの製造方法 | |
| JPS60192706A (ja) | 診断試薬用ラテツクスの製造方法 | |
| JPS5850645B2 (ja) | ラテツクスの製造方法 | |
| JPS5850646B2 (ja) | 血清学的診断試薬用ラテツクスの製造方法 | |
| JPS63228069A (ja) | 診断薬用ラテツクス、その製法および該ラテツクスを用いてなる診断薬 | |
| JPH0157688B2 (enrdf_load_stackoverflow) | ||
| JPH0136484B2 (enrdf_load_stackoverflow) | ||
| JPS62218867A (ja) | 免疫試薬用ラテツクス | |
| JPH0743383B2 (ja) | 診断試薬用担体ラテツクス | |
| JPH038363B2 (enrdf_load_stackoverflow) | ||
| JPH0157687B2 (enrdf_load_stackoverflow) | ||
| JPS59179609A (ja) | 診断試薬用ラテツクスの製造方法 | |
| JPS5915321B2 (ja) | 血清学的診断試薬用ラテツクスの製造方法 | |
| JP3038769B2 (ja) | 診断薬用担体用ポリマー粒子の製造方法 |